Tag: FTSE 100

MAZEN DARWAZEH-MENA CEO of Hikma Pharmaceutical

Venture at 10-Mazen Darwazeh

Mazen Darwazeh: Vice-Chairman and MENA CEO of Hikma Date of Interview: October 2013 Hikma is one of a handful of Jordanian companies that can truly be considered world class. In the first half of 2013, its revenues reached $638.3 million….

Hikma Acquires Roxane Laboratories

In a move that is set to transform its position in the US generics market, Hikma Pharmaceuticals has announced that it is acquiring Roxane Laboratories for JD1.88 billion ($2.65 billion) in cash and stock. Hikma, which was one of a number…

Samih Darwazah: Losing a Legend

Samih Darwazah, the founder of Hikma Pharmaceuticals, died on Friday at the age 85. Long a towering figure in Jordan’s business community for creating such an important firm, he was also one of the country’s first pharmacists, and served both as…

Hikma to graduate to FTSE 100

Hikma Pharmaceuticals is set this month to take its place alongside GlaxoSmithKline, AstraZeneca and Shire as a fourth blue-chip drug maker on the FTSE 100, Britain’s benchmark share index. Hikma will push Tullow Oil out of the esteemed club of…